SCHEMBL3119611

SCHEMBL3119611

CC(=O)c1ccc(C)cc1I

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.42
KDM4E B2RXH2 2/20 0.42
HSD17B10 Q99714 1/20 0.42
KMT2A Q03164 3/20 0.41
CSNK2A1 P68400 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
ALDH1A1 P00352 4/20 0.40
GAA P10253 2/20 0.37
MAPT P10636 2/20 0.37
HTT P42858 2/20 0.37
HPGD P15428 2/20 0.37
CYP3A4 P08684 1/20 0.37
MAPK1 P28482 1/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
POLB P06746 1/20 0.36
LMNA P02545 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
HDAC7 Q8WUI4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29688801 1.00 CYP2A6 (0.42) CYP2A6KDM4EHSD17B10KMT2ACSNK2A1
SCHEMBL9741686 0.83 CSNK2A1 (0.55) KMT2ACSNK2A1SMN1; SMN2ALDH1A1MAPT
SCHEMBL11341497 0.83 CSNK2A1 (0.45) CYP2A6KDM4EHSD17B10KMT2ACSNK2A1
SCHEMBL15066436 0.81 PARP1 (0.44) KDM4EKMT2ACSNK2A1SMN1; SMN2ALDH1A1
SCHEMBL27910231 0.81 CSNK2A1 (0.39) KMT2ACSNK2A1SMN1; SMN2HPGDNPC1
SCHEMBL28879905 0.80 TTR (0.39) KDM4EKMT2ASMN1; SMN2ALDH1A1GAA
SCHEMBL12986352 0.79 CSNK2A1 (0.50) CYP2A6KDM4EHSD17B10KMT2ACSNK2A1
SCHEMBL22374250 0.78 HSD17B1 (0.46) KDM4EHSD17B10KMT2ASMN1; SMN2ALDH1A1
SCHEMBL12124270 0.78 KMT2A (0.41) HSD17B10KMT2ACSNK2A1SMN1; SMN2GAA
SCHEMBL29381894 0.77 KMT2A (0.51) CYP2A6KDM4EHSD17B10KMT2ACSNK2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234925-A1 GPR52 MODULATORS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. 2023-07-27 US disclosed
CN-114835622-A N-tert-butyl protection-3-substituted indole compound and preparation method thereof 常州大学 2022-08-02 CN disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed
US-8372867-B2 Insecticidal aryl isoxazoline derivatives BAYER CROPSCIENCE AG (DE) 2013-02-12 US disclosed
US-20100179194-A1 INSECTICIDAL ARYL ISOXAZOLINE DERIVATIVES BAYER CORPSCIENCE AG (DE) 2010-07-15 US disclosed
EP-2181100-A2 INSECTICIDAL ARYL ISOXAZOLINE DERIVATIVES Bayer CropScience AG (DE) 2010-05-05 EP disclosed
WO-2008122375-A2 INSECTICIDAL ARYL ISOXAZOLINE DERIVATIVES BAYER CROPSCIENCE AG (DE) 2008-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179194-A1 INSECTICIDAL ARYL ISOXAZOLINE DERIVATIVES CYP4X1, AADAC, CYP3A7 CYP2A6 127/4885KDM4E 1090/4885HSD17B10 383/4885
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 CYP2A6 801/4885KDM4E 725/4885HSD17B10 1345/4885
US-20230234925-A1 GPR52 MODULATORS AND METHODS OF USE GPR52, GPR68, GPR35 CYP2A6 1030/4885KDM4E 4664/4885HSD17B10 1107/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 CYP2A6 635/4885KDM4E 723/4885HSD17B10 1748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.